Sagimet Biosciences (SGMT) Change in Accured Expenses (2022 - 2026)

Sagimet Biosciences' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $637000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 81.21% year-over-year to $637000.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 155.87% YoY), while the FY2025 annual figure was $929000.0, up 202.43% from the prior year.
• Change in Accured Expenses was $637000.0 for Q1 2026 at Sagimet Biosciences, up from -$4.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.4 million in Q1 2025 to a low of -$4.0 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $55266.7 across 5 years, with a median of $320000.0 in 2023.
• Biggest YoY gain for Change in Accured Expenses was 533.5% in 2025; the steepest drop was 994.82% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2022, then jumped by 131.84% to $320000.0 in 2023, then jumped by 38.75% to $444000.0 in 2024, then tumbled by 994.82% to -$4.0 million in 2025, then soared by 116.03% to $637000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $637000.0 (Q1 2026), -$4.0 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.